Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Dermatology by Answers in CME. Benefit from ...
Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers
Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.
-------- Â
14:11
Erin Barrett (Wei), MD - Focusing on the Patient to Enhance Therapeutic Care: Advancing Early Diagnosis and Management of Bullous Pemphigoid
Please visit answersincme.com/ZPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the diagnosis and treatment of bullous pemphigoid. Upon completion of this activity, participants should be better able to: Review the clinical impact of bullous pemphigoid (BP) on patients; Outline diagnostic approaches to enhance the timely identification of patients with BP; and Identify clinical advances that may evolve the therapeutic paradigm for patients with BP.
-------- Â
15:10
Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice
Please visit answersincme.com/JZC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the use of immunotherapy in advanced, unresectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Review current evidence-based recommendations informing the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; Describe the clinical profiles of immunotherapies for the treatment of patients with unresectable, locally advanced, recurrent, or metastatic CSCC; and Outline potential considerations to optimize outcomes for patients with unresectable, locally advanced, recurrent, or metastatic CSCC who are on immunotherapies.
-------- Â
15:35
Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma
Please visit answersincme.com/UCA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the management of advanced basal cell carcinoma (BCC) with systemic therapy. Upon completion of this activity, participants should be better able to: Identify patients with BCC who are candidates for a systemic approach to treatment; Review the clinical implications of the evidence on approved and emerging systemic therapies in patients with advanced BCC; and Describe practical strategies to optimize systemic treatment over the long term for patients with advanced BCC. This activity is intended for US healthcare professionals only.
-------- Â
13:42
Ahmad Tarhini, MD, PhD - Adjuvant Approaches in High-Risk, Resectable Melanoma: A Practical Guide to Improving Outcomes With Immunotherapy-Based Regimens
Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the treatment of resectable melanoma; Describe the key adverse events associated with adjuvant immunotherapy for the treatment of resectable melanoma; Outline evidence-based, patient centric strategies to optimize the benefit-to-risk impact of adjuvant immunotherapy in resectable melanoma care
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Dermatology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for dermatologists to cover the diagnosis, treatment, follow-up, and clinical management of various skin conditions. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.